Compare Align Technology, Inc. (ALGN) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Align Technology, Inc. vs Novavax Inc — how do they compare? Align Technology, Inc. trades at $174.45 (market cap $12.29B), while Novavax Inc trades at $7.95 (market cap $1.31B). The key difference: Align Technology, Inc. is far larger — about 9.4× Novavax Inc's market cap, and Align Technology, Inc. is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| ALGN | NVAX | |
|---|---|---|
Market Cap | $12.29B | $1.31B |
Sector | Health | Health |
52-Week High | $197.51 | $11.19 |
52-Week Low | $124.88 | $6.22 |
Enterprise Value | $11.30B | $889.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALGN trades at $173.4, down 1.5% today, amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, a P/E of 30.03, and a net income margin of 9.99%. Recent news highlights a patent win in China and strategic initiatives under activist investor engagement, supporting its digital orthodontics leadership.
Outlook remains positive due to solid profitability and growth initiatives, but risks include competitive pressures and scanner segment weakness. Analyst consensus is strongly bullish with 73% buy ratings, viewing current valuation as attractive for long-term growth despite near-term technical headwinds.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Align Technology, Inc.
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
